See Adipotide dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Adipotide (FTPP) is a chimeric proapoptotic peptide engineered to selectively bind prohibitin on adipose vasculature and trigger endothelial apoptosis, with preclinical primate work showing sustained weight loss. It is one of the more mechanistically distinct compounds in the broader weight-loss research class. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when reconstituting Adipotide.
Adipotide is the research name for FTPP — the prohibitin-targeting chimeric proapoptotic peptide developed by Wadih Arap and Renata Pasqualini and colleagues at the University of Texas MD Anderson Cancer Center. The molecule is conceptually unlike any GLP-1, leptin-analog, or central-appetite-suppressant approach to weight loss: it is a CKGGRAKDC-GG-D(KLAKLAK)2 chimeric construct in which a homing peptide (CKGGRAKDC) selectively binds prohibitin on the endothelium of adipose-tissue vasculature, while a fused proapoptotic mitochondrial-membrane-disrupting domain (D(KLAKLAK)2) triggers endothelial cell apoptosis once the molecule is concentrated at the adipose vascular bed.
Adipotide (FTPP, "fat-targeted pro-apoptotic peptide") is a chimeric peptide most often sourced for fat-loss research that works by targeting the blood supply of white fat tissue. It is a pre-clinical compound with very limited human data. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
The targeting half (CKGGRAKDC) recognises prohibitin, a protein anomalously enriched on the endothelium of white adipose tissue vasculature but not on the vasculature of most other tissues. Once delivered to those endothelial cells, the D(KLAKLAK)2 portion partitions into mitochondrial membranes and triggers apoptosis of the white-adipose endothelium, causing ablation of the local vascular supply and subsequent involution of the surrounding adipocytes by ischemia. This is a vasculature-targeted ablation mechanism distinct from the appetite/incretin mechanisms of GLP-1 class drugs.
Kolonin/Arap/Pasqualini reported substantial weight loss and adipose-mass reduction in obese mice and (in their 2011 Sci Transl Med paper) in obese rhesus macaques. An early-phase human study in obese prostate-cancer patients was initiated at MD Anderson Cancer Center but the program has not advanced to widespread clinical use, and renal-toxicity concerns from the preclinical and pilot human work limit further development. No FDA-approved Adipotide product exists.
Adipotide has a reported half-life of ~2 hours (estimated), and the dose intervals researchers model most often fall around once daily. Clears quickly, so each daily dose works on its own with little carryover. The effect comes from repeated daily exposure rather than a steady blood level. It is catalogued under Weight Loss on WPA.
20 Adipotide reconstitution calculations have been logged by the WPA community. The most common dose entered is 500mcg (5 calculations). The most common bacteriostatic water volume is 3mL. The most popular vial size is 10mg (18 sessions). The most common dosing frequency is daily (7x/week) (1 logged protocols).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.